Skip to main content

Latest Supplement

  • Best Practices: Education for Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors

    For many patients with non–small-cell lung cancer (NSCLC), immunotherapy is now becoming the standard of care. Immunotherapy given as monotherapy or in combination with other agents has contributed to promising results in NSCLC, with the earliest results observed in 2015 with nivolumab, and subsequently leading to FDA approval of 6 agents.
Back to Top